The diagnostic criteria for Alzheimer's disease have evolved over the past 25 years to incorporate biomarkers and define the disease from preclinical to dementia stages. Recent criteria proposed by the National Institute on Aging and Alzheimer's Association aim to provide a unified framework accounting for biomarkers to support clinical diagnosis. While biomarkers show Alzheimer's pathology may precede symptoms, the criteria caution about their validation and relationship to symptom onset is still unclear. The diagnostic process first determines if a patient meets criteria for dementia by showing impairments in memory and at least one other cognitive domain significantly impacting functioning.
The diagnosis of dementia due to Alzheimer’s diseaseDario Yac
The document presents revised criteria for diagnosing Alzheimer's disease (AD) dementia put forth by a workgroup convened by the National Institute on Aging and the Alzheimer's Association. The summary is:
1. The workgroup updated the 1984 NINCDS-ADRDA criteria for AD dementia to incorporate advances in understanding of AD pathology and clinical presentation, as well as biomarkers.
2. The revised criteria distinguish between all-cause dementia, probable AD dementia based on clinical criteria alone, and probable or possible AD dementia when biomarkers are also considered.
3. Probable AD dementia requires a gradual onset of cognitive decline in one of several domains including memory, language, visuospatial skills or executive function.
Toward defining the preclinical stages of Alzheimer's diseaseDario Yac
1) The document discusses recommendations from a workgroup on defining the preclinical stages of Alzheimer's disease.
2) It proposes a conceptual framework that defines Alzheimer's disease as encompassing the underlying pathophysiological process (AD-P) rather than just the clinical stages of the disease.
3) The framework suggests there is a long asymptomatic period during which the pathological process is progressing, and individuals may be at increased risk for future cognitive impairment even if symptoms have not emerged yet.
Introduction to Revised Criteria for the Diagnosis of Alzheimer’s DiseaseDario Yac
This document introduces revised criteria for diagnosing Alzheimer's disease from the National Institute on Aging and the Alzheimer's Association. It discusses advances in understanding AD since the original 1984 criteria. The revised criteria distinguish between AD pathophysiological processes and clinical symptoms. Biomarkers of amyloid and neuronal degeneration are incorporated formally. The criteria are intended to better account for the gradual progression of cognitive impairment in AD and differences from other dementias.
The diagnosis of mild cognitive impairment due to Alzheimer’s disease:Dario Yac
The document provides recommendations from a workgroup on criteria for mild cognitive impairment (MCI) due to Alzheimer's disease (AD). It outlines two sets of criteria:
1. Core clinical criteria for MCI diagnosis that do not require biomarkers and can be used in any clinical setting. This includes evidence of cognitive decline from the patient or informant and impairment in one or more cognitive domains with preserved functional abilities.
2. Clinical research criteria for use in research settings that incorporate biomarkers based on imaging and cerebrospinal fluid measures. This criteria has four levels of certainty depending on biomarker findings.
Considerable further research is needed to validate the biomarker-based criteria and standardize biomarkers before they can be used
Expert Recommendations for the Laboratory Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 disease): Diagnostic Algorithm and Best Practice Guidelines for a Timely Diagnosis
This document lists 53 publications by Dr. Nelleen Baboolal, including:
1) Peer-reviewed journal articles on topics like dementia research in Trinidad and Tobago, emotional intelligence, and biomarkers for Alzheimer's disease.
2) Book chapters on mental health issues in the Caribbean region and risk factors for Alzheimer's disease.
3) Conference presentations and papers on quantifying EEG waves and determining diagnostic methods for mental illnesses.
4) A dissertation on special educational needs in children.
5) Non-peer reviewed articles in regional medical journals.
6) Other publications such as lecture notes and an educational video.
This document discusses classification and diagnostic issues related to intellectual developmental disorders (IDDs) and mental health. It provides definitions of IDD and discusses debates around using IQ as a criterion. It notes the high rates of psychiatric disorders, autism, and other developmental conditions in individuals with IDD. The document also summarizes research on genetic overlaps between various neurodevelopmental disorders like autism, IDD, and schizophrenia. It discusses specific genes and proteins that have been implicated in cognition and synaptic function, and the role of these genes across multiple mental health conditions.
Early signs and symptoms of childhood onset neuronal ceroid lipofuscinosis (NCL) subtypes were identified through a literature review. The most common age of onset is between two and five years. Early symptoms include neurological regression, speech delay, ataxia, and seizures. Facilitators of early diagnosis include parents identifying subtle symptoms and increased awareness among healthcare professionals, while lack of awareness and subtle initial symptoms can hinder diagnosis.
The diagnosis of dementia due to Alzheimer’s diseaseDario Yac
The document presents revised criteria for diagnosing Alzheimer's disease (AD) dementia put forth by a workgroup convened by the National Institute on Aging and the Alzheimer's Association. The summary is:
1. The workgroup updated the 1984 NINCDS-ADRDA criteria for AD dementia to incorporate advances in understanding of AD pathology and clinical presentation, as well as biomarkers.
2. The revised criteria distinguish between all-cause dementia, probable AD dementia based on clinical criteria alone, and probable or possible AD dementia when biomarkers are also considered.
3. Probable AD dementia requires a gradual onset of cognitive decline in one of several domains including memory, language, visuospatial skills or executive function.
Toward defining the preclinical stages of Alzheimer's diseaseDario Yac
1) The document discusses recommendations from a workgroup on defining the preclinical stages of Alzheimer's disease.
2) It proposes a conceptual framework that defines Alzheimer's disease as encompassing the underlying pathophysiological process (AD-P) rather than just the clinical stages of the disease.
3) The framework suggests there is a long asymptomatic period during which the pathological process is progressing, and individuals may be at increased risk for future cognitive impairment even if symptoms have not emerged yet.
Introduction to Revised Criteria for the Diagnosis of Alzheimer’s DiseaseDario Yac
This document introduces revised criteria for diagnosing Alzheimer's disease from the National Institute on Aging and the Alzheimer's Association. It discusses advances in understanding AD since the original 1984 criteria. The revised criteria distinguish between AD pathophysiological processes and clinical symptoms. Biomarkers of amyloid and neuronal degeneration are incorporated formally. The criteria are intended to better account for the gradual progression of cognitive impairment in AD and differences from other dementias.
The diagnosis of mild cognitive impairment due to Alzheimer’s disease:Dario Yac
The document provides recommendations from a workgroup on criteria for mild cognitive impairment (MCI) due to Alzheimer's disease (AD). It outlines two sets of criteria:
1. Core clinical criteria for MCI diagnosis that do not require biomarkers and can be used in any clinical setting. This includes evidence of cognitive decline from the patient or informant and impairment in one or more cognitive domains with preserved functional abilities.
2. Clinical research criteria for use in research settings that incorporate biomarkers based on imaging and cerebrospinal fluid measures. This criteria has four levels of certainty depending on biomarker findings.
Considerable further research is needed to validate the biomarker-based criteria and standardize biomarkers before they can be used
Expert Recommendations for the Laboratory Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 disease): Diagnostic Algorithm and Best Practice Guidelines for a Timely Diagnosis
This document lists 53 publications by Dr. Nelleen Baboolal, including:
1) Peer-reviewed journal articles on topics like dementia research in Trinidad and Tobago, emotional intelligence, and biomarkers for Alzheimer's disease.
2) Book chapters on mental health issues in the Caribbean region and risk factors for Alzheimer's disease.
3) Conference presentations and papers on quantifying EEG waves and determining diagnostic methods for mental illnesses.
4) A dissertation on special educational needs in children.
5) Non-peer reviewed articles in regional medical journals.
6) Other publications such as lecture notes and an educational video.
This document discusses classification and diagnostic issues related to intellectual developmental disorders (IDDs) and mental health. It provides definitions of IDD and discusses debates around using IQ as a criterion. It notes the high rates of psychiatric disorders, autism, and other developmental conditions in individuals with IDD. The document also summarizes research on genetic overlaps between various neurodevelopmental disorders like autism, IDD, and schizophrenia. It discusses specific genes and proteins that have been implicated in cognition and synaptic function, and the role of these genes across multiple mental health conditions.
Early signs and symptoms of childhood onset neuronal ceroid lipofuscinosis (NCL) subtypes were identified through a literature review. The most common age of onset is between two and five years. Early symptoms include neurological regression, speech delay, ataxia, and seizures. Facilitators of early diagnosis include parents identifying subtle symptoms and increased awareness among healthcare professionals, while lack of awareness and subtle initial symptoms can hinder diagnosis.
1) Generalized Anxiety Disorder (GAD) is highly prevalent, affecting approximately 2% of the population annually, yet it often goes undiagnosed.
2) GAD frequently presents with medically unexplained symptoms like insomnia or pain rather than anxiety itself, making it challenging to diagnose. It also commonly co-occurs with other psychiatric or medical conditions.
3) While GAD has a substantial personal and economic burden, primary care physicians correctly diagnose it in only about one-third of cases. Better physician education is needed to improve recognition and management of GAD.
The document discusses Alzheimer's disease and dementia. It provides epidemiological data showing that the number of people with Alzheimer's is increasing significantly and will rise to over 40 million worldwide by 2025. It describes the diagnostic criteria and clinical presentation of different types of dementia including Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, and rapidly progressive dementias like Creutzfeldt-Jakob disease. It discusses tools for assessing cognition and mental status in diagnosing dementia.
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...HTAi Bilbao 2012
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Health Technology Assessment
Jackie Tran, MD
University of Medicine and Dentistry of New Jersey, USA
HTAi 9th Annual Meeting, Bilbao
Integrated Care for a Patient Centered System
25 June, 2012
This document contains abstracts from research, innovations, and clinical vignettes presented at the 2011 Hospital Medicine annual meeting. The abstracts are divided into sections for research, innovations, and clinical vignettes. Some of the abstracts presented include evaluations of HIV screening practices, the safety of arthrocentesis for patients on warfarin therapy, incidence of venous thromboembolism in homebound patients, and an assessment of pain in patients undergoing bone marrow biopsies. The abstracts cover a wide range of topics in hospital medicine and include results from studies, innovations, and case reports.
FACTORES ASOCIADOS A LA FALTA DE ESPERANZAKaierleiki
This study examined the prevalence and factors associated with hopelessness in a population sample of 1,722 adults in Finland. The researchers found that 11% of subjects reported at least moderate hopelessness. Factors independently associated with higher odds of hopelessness included poor financial situation, poor subjective health, and reduced working ability. Subjects who were dissatisfied with life, depressed, had alexithymia (difficulty identifying and describing emotions), or suicidal ideation also had significantly higher odds of moderate or severe hopelessness. The study demonstrated a moderately high prevalence of hopelessness in the general population and identified important indicators of low subjective well-being that healthcare providers should be aware of.
This document discusses biomarkers for epileptogenesis and the challenges in developing clinically useful biomarkers to predict epilepsy risk, progression, and treatment response. It notes that while many potential biomarkers have been identified in preclinical studies, none have translated to clinical use. Some key challenges include the long timescales between injury and seizures, heterogeneity of epilepsy types and patients, and a focus on retrospective studies in refractory epilepsy patients rather than prospective validation. The document argues that combinatorial biomarkers analyzing multiple mechanisms may be more promising than single biomarkers, and that biomarkers should be validated as direct measures of patient outcomes rather than relying solely on seizure occurrence.
This document summarizes research on non-specific low back pain. It discusses the epidemiology, including the high lifetime prevalence and risk of recurrence. While mechanical factors may not play a major role, genetic factors are important. Clinical imaging should only be used restrictively for diagnosis, as many imaging findings are common in asymptomatic individuals. Treatments have unclear mechanisms and low effect sizes; self-management is generally recommended over surgery or overtreatment.
The document provides an overview of the Canadian Consensus Document on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It summarizes the development of the consensus document, which was spearheaded by the National ME/FM Action Network of Canada in response to the need for a clinical case definition and guidelines for diagnosis and treatment of ME/CFS. An expert panel of 11 clinicians and researchers with experience treating over 20,000 ME/CFS patients was selected to develop the consensus document. The panel held a funded workshop to reach consensus on a clinical case definition, diagnostic guidelines, and treatment guidelines for medical practitioners dealing with ME/CFS patients.
Ccf neuro res rapidly progressive dementia 2013 03-27applebyb
Rapidly progressive dementia can be caused by many conditions, not just prion diseases. Prion diseases should not be the default diagnosis, as there are treatable and reversible causes that could be missed. While diagnostic tests like CSF 14-3-3, EEG, and brain MRI findings can support a prion disease diagnosis, they are not specific and can be present in other non-prion conditions as well. A thorough evaluation is needed to avoid misdiagnosis, and symptomatic treatment should still be considered even for prion diseases.
Neurosarcoidosis is a rare condition where sarcoidosis affects the nervous system. It can be difficult to diagnose as it often presents with non-specific neurological symptoms. Diagnosis requires a combination of CSF analysis, MRI imaging showing characteristic abnormalities, and biopsy evidence of granulomas. A multidisciplinary team approach is needed to manage this complex condition.
There is Time to Adjust. Aging as a Protective Factor for Autism-Crimson Publ...CrimsonPublishersGGS
There is Time to Adjust. Aging as a Protective Factor for Autism by Diego Iacono in Gerontology & Geriatrics studies
Autism spectrum disorder (ASD) is formally diagnosed before the age of 3 that is, when the central nervous system (CNS) is not yet completely formed, but it is mature enough to generate behavioural abnormalities in some individuals when compared to an age- matched group of typically developed children [1,2]. However, ASD is not a life-threating disease and children diagnosed with ASD age at the same rate as their peers. The possible detrimental or beneficial factors associated with aging in children affected by ASD are not fully known. Surprisingly, the amount of peer-reviewed medical and scientific international literature published on the topic of aging with autism is quite modest and sporadic [3]. The scarcity of aging-ASD investigations derives from the lower level of attention, and related funding opportunities, from the major public and private funding agencies for research across the globe
el mundo desarrollado tiene un mayor indice de epilepsia, Nuevos conocimientos sobre las causas y consecuencias de la epilepsia en los países en desarrollo ofrecen oportunidad para la prevención y / o tratamiento mejorado, que se complementan con las directrices publicadas recientemente epilepsia cuidado para su uso en este entorno
This document summarizes research on the course and outcome of schizophrenia. It discusses several landmark studies including the International Pilot Study of Schizophrenia, Determinants of Outcome of Severe Mental Disorder study, and International Study of Schizophrenia. Overall, the studies found that outcomes tended to be better in developing countries compared to developed countries. Within developing countries, outcomes were particularly good in India, with studies in Agra and Chandigarh finding high rates of remission. Acute onset, good premorbid adjustment, younger age, and shorter duration of initial psychotic episode predicted better long-term prognosis.
This document provides guidelines from the 2012 American College of Rheumatology for the management of gout, focusing on non-pharmacologic and pharmacologic approaches to hyperuricemia. It recommends patient education as a core treatment, and xanthine oxidase inhibitors such as allopurinol or febuxostat as first-line urate-lowering therapy. The target serum urate level is less than 6 mg/dl and often less than 5 mg/dl. It also addresses treatment of chronic tophaceous gouty arthritis and the use of pegloticase for severe refractory gout.
This document provides an overview and summary of a presentation on assessing pain, sedation, and delirium in intensive care unit patients. It discusses:
- The importance of using validated scales like the Richmond Agitation-Sedation Scale (RASS) and Sedation-Agitation Scale (SAS) to accurately assess sedation levels in patients receiving sedatives.
- The challenges of assessing delirium given confounding factors like a patient's sedation level, wakefulness, and other psychiatric diagnoses. Scales like the Confusion Assessment Method for the ICU (CAM-ICU) are used but their accuracy depends on a patient's sedation.
- How pharmacokinetic factors like drug-
- An acute gouty arthritis attack should be treated with pharmacologic therapy initiated within 24 hours of onset. Established urate-lowering therapy should be continued without interruption during an attack.
- Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or oral colchicine are appropriate first-line options for treating acute gout. Certain combinations can be used for severe or refractory attacks.
- Pharmacologic anti-inflammatory prophylaxis is recommended for all gout patients starting urate-lowering therapy and should continue if gout disease activity persists or serum urate target is unmet. Oral colchicine is an appropriate first-line option
23 September 2010 - National Council for Palliative Care / National End of Life Care Programme / the neurological alliance 15 February 2013 - National End of Life Care Programme / Whole Systems Partnership
This document aims to set out an EoLC framework for implementation that speciï¬cally meets the needs of those with neurological conditions.
It covers:
Strategic context
End of life care tools
End of life care in neurological disease
Communication and advance care planning
Co-ordination and multidisciplinary approach to care
Management of physical symptoms
Holistic care - psychosocial and spiritual aspects
Care at the end of life
Carers
Workforce, education and training
Commissioning health and social care services
Neurocysticercosis the notorious vanishing ring enhancing lesion ijar feb 2015Sachin Adukia
This document summarizes a study of 25 patients presenting with ring enhancing lesions (RELs) on MRI brain scans. The study aimed to evaluate clinical features and diagnoses of RELs and treatment outcomes. Of the 25 patients, 8 (32%) were diagnosed with neurocysticercosis based on clinical features, investigations and MRI findings. All 8 neurocysticercosis patients presented with seizures and most with headache. Lesions were typically solitary and less than 10mm. Treatment with albendazole, anti-convulsants and steroids resulted in complete resolution in 6 patients (75%) and regression/calcification in the remaining 2, demonstrating neurocysticercosis has an excellent prognosis with appropriate treatment.
Most people with dementia undergo behavioral changes during the course of the disease. They may become anxious or repeat the same question or activity over and over. The unpredictability of these changes can be stressful for caregivers. As the disease progresses, your loved one's behavior may seem inappropriate, childlike or impulsive. Anticipating behavioral changes and understanding the causes can help you deal with them more effectively.
This document discusses the management of schizophrenia with obsessive-compulsive features. It provides an overview of the epidemiology and pathogenesis of obsessive-compulsive symptoms in schizophrenia. Obsessive-compulsive phenomena are commonly observed in patients with schizophrenia and can manifest in various ways, including as a prodrome, coexisting independent disorder, part of active psychosis, or emerging due to atypical antipsychotic treatment. Neurobiological studies have found similarities and differences in the brain circuitry and structures involved in schizophrenia and obsessive-compulsive disorder. Effective management of obsessive-compulsive symptoms in schizophrenia requires consideration of their various pathogenesis and treatment with antipsychotics or adjunctive antidepressants in some cases.
1) Generalized Anxiety Disorder (GAD) is highly prevalent, affecting approximately 2% of the population annually, yet it often goes undiagnosed.
2) GAD frequently presents with medically unexplained symptoms like insomnia or pain rather than anxiety itself, making it challenging to diagnose. It also commonly co-occurs with other psychiatric or medical conditions.
3) While GAD has a substantial personal and economic burden, primary care physicians correctly diagnose it in only about one-third of cases. Better physician education is needed to improve recognition and management of GAD.
The document discusses Alzheimer's disease and dementia. It provides epidemiological data showing that the number of people with Alzheimer's is increasing significantly and will rise to over 40 million worldwide by 2025. It describes the diagnostic criteria and clinical presentation of different types of dementia including Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, and rapidly progressive dementias like Creutzfeldt-Jakob disease. It discusses tools for assessing cognition and mental status in diagnosing dementia.
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...HTAi Bilbao 2012
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Health Technology Assessment
Jackie Tran, MD
University of Medicine and Dentistry of New Jersey, USA
HTAi 9th Annual Meeting, Bilbao
Integrated Care for a Patient Centered System
25 June, 2012
This document contains abstracts from research, innovations, and clinical vignettes presented at the 2011 Hospital Medicine annual meeting. The abstracts are divided into sections for research, innovations, and clinical vignettes. Some of the abstracts presented include evaluations of HIV screening practices, the safety of arthrocentesis for patients on warfarin therapy, incidence of venous thromboembolism in homebound patients, and an assessment of pain in patients undergoing bone marrow biopsies. The abstracts cover a wide range of topics in hospital medicine and include results from studies, innovations, and case reports.
FACTORES ASOCIADOS A LA FALTA DE ESPERANZAKaierleiki
This study examined the prevalence and factors associated with hopelessness in a population sample of 1,722 adults in Finland. The researchers found that 11% of subjects reported at least moderate hopelessness. Factors independently associated with higher odds of hopelessness included poor financial situation, poor subjective health, and reduced working ability. Subjects who were dissatisfied with life, depressed, had alexithymia (difficulty identifying and describing emotions), or suicidal ideation also had significantly higher odds of moderate or severe hopelessness. The study demonstrated a moderately high prevalence of hopelessness in the general population and identified important indicators of low subjective well-being that healthcare providers should be aware of.
This document discusses biomarkers for epileptogenesis and the challenges in developing clinically useful biomarkers to predict epilepsy risk, progression, and treatment response. It notes that while many potential biomarkers have been identified in preclinical studies, none have translated to clinical use. Some key challenges include the long timescales between injury and seizures, heterogeneity of epilepsy types and patients, and a focus on retrospective studies in refractory epilepsy patients rather than prospective validation. The document argues that combinatorial biomarkers analyzing multiple mechanisms may be more promising than single biomarkers, and that biomarkers should be validated as direct measures of patient outcomes rather than relying solely on seizure occurrence.
This document summarizes research on non-specific low back pain. It discusses the epidemiology, including the high lifetime prevalence and risk of recurrence. While mechanical factors may not play a major role, genetic factors are important. Clinical imaging should only be used restrictively for diagnosis, as many imaging findings are common in asymptomatic individuals. Treatments have unclear mechanisms and low effect sizes; self-management is generally recommended over surgery or overtreatment.
The document provides an overview of the Canadian Consensus Document on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It summarizes the development of the consensus document, which was spearheaded by the National ME/FM Action Network of Canada in response to the need for a clinical case definition and guidelines for diagnosis and treatment of ME/CFS. An expert panel of 11 clinicians and researchers with experience treating over 20,000 ME/CFS patients was selected to develop the consensus document. The panel held a funded workshop to reach consensus on a clinical case definition, diagnostic guidelines, and treatment guidelines for medical practitioners dealing with ME/CFS patients.
Ccf neuro res rapidly progressive dementia 2013 03-27applebyb
Rapidly progressive dementia can be caused by many conditions, not just prion diseases. Prion diseases should not be the default diagnosis, as there are treatable and reversible causes that could be missed. While diagnostic tests like CSF 14-3-3, EEG, and brain MRI findings can support a prion disease diagnosis, they are not specific and can be present in other non-prion conditions as well. A thorough evaluation is needed to avoid misdiagnosis, and symptomatic treatment should still be considered even for prion diseases.
Neurosarcoidosis is a rare condition where sarcoidosis affects the nervous system. It can be difficult to diagnose as it often presents with non-specific neurological symptoms. Diagnosis requires a combination of CSF analysis, MRI imaging showing characteristic abnormalities, and biopsy evidence of granulomas. A multidisciplinary team approach is needed to manage this complex condition.
There is Time to Adjust. Aging as a Protective Factor for Autism-Crimson Publ...CrimsonPublishersGGS
There is Time to Adjust. Aging as a Protective Factor for Autism by Diego Iacono in Gerontology & Geriatrics studies
Autism spectrum disorder (ASD) is formally diagnosed before the age of 3 that is, when the central nervous system (CNS) is not yet completely formed, but it is mature enough to generate behavioural abnormalities in some individuals when compared to an age- matched group of typically developed children [1,2]. However, ASD is not a life-threating disease and children diagnosed with ASD age at the same rate as their peers. The possible detrimental or beneficial factors associated with aging in children affected by ASD are not fully known. Surprisingly, the amount of peer-reviewed medical and scientific international literature published on the topic of aging with autism is quite modest and sporadic [3]. The scarcity of aging-ASD investigations derives from the lower level of attention, and related funding opportunities, from the major public and private funding agencies for research across the globe
el mundo desarrollado tiene un mayor indice de epilepsia, Nuevos conocimientos sobre las causas y consecuencias de la epilepsia en los países en desarrollo ofrecen oportunidad para la prevención y / o tratamiento mejorado, que se complementan con las directrices publicadas recientemente epilepsia cuidado para su uso en este entorno
This document summarizes research on the course and outcome of schizophrenia. It discusses several landmark studies including the International Pilot Study of Schizophrenia, Determinants of Outcome of Severe Mental Disorder study, and International Study of Schizophrenia. Overall, the studies found that outcomes tended to be better in developing countries compared to developed countries. Within developing countries, outcomes were particularly good in India, with studies in Agra and Chandigarh finding high rates of remission. Acute onset, good premorbid adjustment, younger age, and shorter duration of initial psychotic episode predicted better long-term prognosis.
This document provides guidelines from the 2012 American College of Rheumatology for the management of gout, focusing on non-pharmacologic and pharmacologic approaches to hyperuricemia. It recommends patient education as a core treatment, and xanthine oxidase inhibitors such as allopurinol or febuxostat as first-line urate-lowering therapy. The target serum urate level is less than 6 mg/dl and often less than 5 mg/dl. It also addresses treatment of chronic tophaceous gouty arthritis and the use of pegloticase for severe refractory gout.
This document provides an overview and summary of a presentation on assessing pain, sedation, and delirium in intensive care unit patients. It discusses:
- The importance of using validated scales like the Richmond Agitation-Sedation Scale (RASS) and Sedation-Agitation Scale (SAS) to accurately assess sedation levels in patients receiving sedatives.
- The challenges of assessing delirium given confounding factors like a patient's sedation level, wakefulness, and other psychiatric diagnoses. Scales like the Confusion Assessment Method for the ICU (CAM-ICU) are used but their accuracy depends on a patient's sedation.
- How pharmacokinetic factors like drug-
- An acute gouty arthritis attack should be treated with pharmacologic therapy initiated within 24 hours of onset. Established urate-lowering therapy should be continued without interruption during an attack.
- Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or oral colchicine are appropriate first-line options for treating acute gout. Certain combinations can be used for severe or refractory attacks.
- Pharmacologic anti-inflammatory prophylaxis is recommended for all gout patients starting urate-lowering therapy and should continue if gout disease activity persists or serum urate target is unmet. Oral colchicine is an appropriate first-line option
23 September 2010 - National Council for Palliative Care / National End of Life Care Programme / the neurological alliance 15 February 2013 - National End of Life Care Programme / Whole Systems Partnership
This document aims to set out an EoLC framework for implementation that speciï¬cally meets the needs of those with neurological conditions.
It covers:
Strategic context
End of life care tools
End of life care in neurological disease
Communication and advance care planning
Co-ordination and multidisciplinary approach to care
Management of physical symptoms
Holistic care - psychosocial and spiritual aspects
Care at the end of life
Carers
Workforce, education and training
Commissioning health and social care services
Neurocysticercosis the notorious vanishing ring enhancing lesion ijar feb 2015Sachin Adukia
This document summarizes a study of 25 patients presenting with ring enhancing lesions (RELs) on MRI brain scans. The study aimed to evaluate clinical features and diagnoses of RELs and treatment outcomes. Of the 25 patients, 8 (32%) were diagnosed with neurocysticercosis based on clinical features, investigations and MRI findings. All 8 neurocysticercosis patients presented with seizures and most with headache. Lesions were typically solitary and less than 10mm. Treatment with albendazole, anti-convulsants and steroids resulted in complete resolution in 6 patients (75%) and regression/calcification in the remaining 2, demonstrating neurocysticercosis has an excellent prognosis with appropriate treatment.
Most people with dementia undergo behavioral changes during the course of the disease. They may become anxious or repeat the same question or activity over and over. The unpredictability of these changes can be stressful for caregivers. As the disease progresses, your loved one's behavior may seem inappropriate, childlike or impulsive. Anticipating behavioral changes and understanding the causes can help you deal with them more effectively.
This document discusses the management of schizophrenia with obsessive-compulsive features. It provides an overview of the epidemiology and pathogenesis of obsessive-compulsive symptoms in schizophrenia. Obsessive-compulsive phenomena are commonly observed in patients with schizophrenia and can manifest in various ways, including as a prodrome, coexisting independent disorder, part of active psychosis, or emerging due to atypical antipsychotic treatment. Neurobiological studies have found similarities and differences in the brain circuitry and structures involved in schizophrenia and obsessive-compulsive disorder. Effective management of obsessive-compulsive symptoms in schizophrenia requires consideration of their various pathogenesis and treatment with antipsychotics or adjunctive antidepressants in some cases.
This document proposes revising the diagnostic criteria for Alzheimer's disease (AD) to better capture the earliest stages of the disease before full dementia. The current NINCDS-ADRDA criteria have low specificity for differentiating AD from other dementias. New biomarkers from neuroimaging and cerebrospinal fluid now enable more definitive identification of AD pathology. The proposed revisions center on early episodic memory impairment and require at least one abnormal biomarker. Revised criteria are needed to reliably identify AD at its earliest stages to better test emerging disease-modifying therapies aimed at preventing progression to dementia.
Hypothetical model of dynamic biomarkers of the alzheimer pathological cascadeCarolinaRamrez60
The document presents a hypothetical model of biomarkers for Alzheimer's disease progression. It proposes that:
1) Abnormal amyloid beta processing occurs first, before symptoms, which is detected by reduced CSF Aβ42 and increased amyloid PET tracer retention.
2) After a lag period, neuronal dysfunction and neurodegeneration become dominant, detected by increased CSF tau and brain atrophy on structural MRI.
3) Neurodegeneration is accompanied by synaptic dysfunction detected by decreased fluorodeoxyglucose uptake on PET.
4) The model relates disease stage to biomarkers, with amyloid biomarkers becoming abnormal first before neurodegenerative biomarkers and symptoms, which then correlate with severity.
This document provides an overview of schizophrenia including its description, causes, signs and symptoms, diagnosis, treatment, and prognosis. Schizophrenia is a severe mental disorder that results in delusions, disordered thinking and behavior, and hallucinations. It is caused by a combination of genetic, chemical, structural, and environmental factors. Treatment involves antipsychotic medication and psychotherapy. While there is no cure, treatment can help manage symptoms and improve quality of life.
Dementia is an umbrella term that can affect even young individuals. This presentation investigates causes, assessment, diagnosis, and treatment options.
The document discusses psychiatric classification systems. It provides an overview of key concepts like nosology, syndrome, disease, and disorder. It describes the purposes of psychiatric classification as communication, control of disorders, and comprehension. It discusses important criteria for a good classification like reliability, validity, utility, and ease of use. Challenges in psychiatric classification are the reliance on subjective reports and lack of objective measures. The document contrasts categorical and dimensional models of classification and provides examples of disorders where a dimensional approach is favored. It provides a brief history of major classification systems and describes current systems like DSM-5 and ICD-11.
This document discusses recent advances in the diagnosis and treatment of schizophrenia and Alzheimer's/dementia. It provides definitions of schizophrenia and Alzheimer's disease, describing them as neurological disorders. The causes, diagnoses, and treatments of each are discussed, along with limitations in current treatments and prospects for future treatment improvements. Biochemical and molecular analyses of both conditions are also reviewed.
2015 Suarez-Gonzalez et al PCA Psychiatr Clin North AmDr Susie Henley
This document summarizes research on neuropsychiatric manifestations (NPM) in posterior cortical atrophy (PCA), an atypical form of Alzheimer's disease. It finds that apathy, anxiety, depression and irritability are the most common NPM in PCA. While NPM rates are high in PCA as in other dementias, the profile may differ in that anxiety is particularly prevalent compared to typical Alzheimer's. Younger age of onset in PCA could also influence NPM patterns compared to late-onset Alzheimer's. The neuropsychiatric examination is important for diagnosis and treatment of NPM in PCA.
This document discusses schizophrenia using a biopsychosocial model. It addresses evidence for brain localization in schizophrenia, genetic factors, and environmental factors. Schizophrenia is a disabling brain disorder affecting self and social functioning. Symptoms include hallucinations, delusions, and disorganized speech. Causes likely involve genetic and environmental factors. Treatment focuses on symptom management using medication and psychosocial support. Studies show common biological mechanisms between schizophrenia and depression. Research also provides preliminary evidence of brain localization and genetic risk factors for schizophrenia.
Three studies found that patients with neurofibromatosis (NF), including NF1 and NF2, reported lower quality of life scores compared to the general population when assessed using the generic SF-36 quality of life measure. Visibility and severity of NF1 symptoms significantly predicted lower skin-specific and general quality of life scores. However, the evidence for specific predictors of quality of life in NF patients was otherwise weak or inconclusive. Given the documented lower quality of life in NF patients, future research should comprehensively examine psychosocial factors and potential mind-body interventions.
1179journal.publications.chestnet.org Th e PathophysSantosConleyha
The document discusses the pathophysiology of insomnia across multiple levels of analysis, with a focus on hyperarousal as a central theme. It summarizes current knowledge on insomnia's genetic, molecular, cellular, and neurological underpinnings. The document proposes a model integrating evidence that insomnia may involve heightened physiological, cognitive, and emotional arousal that interferes with disengagement from the environment and the ability to fall asleep. Understanding insomnia's pathophysiology could provide insights into how and why it develops and is maintained.
This document provides an overview of psychosis in the elderly, including:
- Common causes are schizophrenia, affective disorders like depression, dementia, delirium, and Parkinson's disease.
- Biological factors underlie many psychotic symptoms. Antipsychotics are commonly used to treat psychosis but have risks.
- Psychosis is more prevalent in nursing home populations compared to community samples. As the population ages, cases of psychosis will rise significantly.
- Specific causes like Alzheimer's disease and depression are discussed in more detail, including their prevalence, clinical presentation, treatments and risks.
This document summarizes research on cognitive and behavioral effects in epilepsy. It finds that cognitive impairment is more common in epileptic patients compared to the general population, and the degree of impairment varies depending on the epilepsy syndrome. Behavioral changes are also more common in people with epilepsy, especially those with drug-resistant epilepsy or frequent seizures. For children, factors like epilepsy itself, epilepsy treatment, underlying structural brain abnormalities, and epilepsy syndromes can predict behavioral changes. The document reviews several studies on cognition and behavior in childhood epilepsy and factors linked to changes like structural brain abnormalities, progressive cognitive impairment, and effects of epilepsy treatment.
Epilepsy is a chronic neurological disorder which is caused by various factors which may vary according to the age of patients which results in asynchronization of neurons. Cognitive functional impairment is mostly seen in epileptic patients compared to the general population, and the degree of its impairment varies from one another according to the epilepsy syndrome. Behavioral changes are more seen in epileptic people and people with drug-resistant epilepsy, frequent seizures, and associated neurological or mental abnormalities. In children and adults, many data suggest a correlation between behavior/cognition and some other specific epilepsy syndromes. The major predictors of such behavioral changes in children with epilepsy are epilepsy itself, treatment, the underlying structural lesion, and epilepsy treatment.
This review article discusses cognition and behavioral effects in epilepsy. It notes that cognitive impairment and behavioral changes are commonly seen in epileptic patients compared to the general population. The degree of impairment varies depending on the epilepsy syndrome. In children, behavioral disorders like depression, anxiety and anger are more frequent in epileptic individuals. Several factors are linked to cognitive and behavioral changes in epilepsy patients, including structural brain abnormalities, progressive cognitive impairment from the epilepsy itself, and adverse effects of epilepsy treatment with some antiepileptic drugs. The major predictors of behavioral changes in children are the epilepsy, its treatment, any underlying structural brain lesions, and treatment effects.
This review article discusses cognition and behavioral effects in epilepsy. It finds that cognitive impairment and behavioral changes are more common in epileptic patients compared to the general population. The degree of impairment varies based on the epilepsy syndrome. In children, behavioral disorders like depression and anxiety are more frequent in epileptic children. Several factors are linked to cognitive and behavioral changes in epilepsy patients, including structural brain abnormalities, progressive cognitive impairment from the epilepsy itself, and adverse effects of epilepsy treatment with some antiepileptic drugs. Managing epilepsy and treating with appropriate medications can help reduce these symptoms.
The document summarizes the latest research on Alzheimer's and dementia. It discusses that dementia is an umbrella term for cognitive decline, with Alzheimer's being the most common cause. Research is exploring new biomarkers like tau in blood and brain imaging to aid in early detection and diagnosis. Several drug trials are investigating treatments targeting amyloid and tau to improve cognitive and behavioral symptoms. While risk factors like age, genetics and lifestyle impact disease progression, increasing diversity in clinical trials and considering social factors is important for understanding and addressing health disparities. Overall, advances in research provide hope that earlier detection and more effective therapies may help change the trajectory of Alzheimer's in coming years.
Similar to Evolution of the diagnostic criteria for degenerative and cognitive disorders (20)
La maniobra de Gufoni es una técnica de primeros auxilios para ayudar a una persona que se está ahogando con un objeto atorado en la garganta. Consiste en dar cinco golpes fuertes en la espalda de la persona entre los omóplatos y, si esto no funciona, realizar la compresión abdominal. El objetivo es desatascar los pulmones y las vías respiratorias.
La maniobra de Epley es un procedimiento médico para tratar el vértigo posicional paroxístico benigno. Consiste en colocar la cabeza del paciente en diferentes posiciones para ayudar a los cristales del oído interno a volver a su posición correcta. El objetivo es aliviar los síntomas de mareo y desequilibrio que experimentan las personas con esta afección.
La maniobra de Semont es un procedimiento que ayuda a aliviar el mareo mediante la estimulación del sistema vestibular. Consiste en inclinar la cabeza hacia un lado durante unos minutos para mover las otoconias, pequeñas estructuras del oído interno que detectan la gravedad y la aceleración. Esto puede ayudar a restablecer el equilibrio cuando se experimenta mareo o vértigo.
Actividades para mejorar el rendimiento cognitivoDario Yac
Este documento presenta varias actividades para mejorar el rendimiento cognitivo como sopas de letras con diferentes temas, crucigramas sobre películas infantiles, laberintos, adivinar letras faltantes y colorear mandalas, todo lo cual ejercita funciones como la vista, la memoria y la resolución de problemas.
El documento habla sobre el olvido en el envejecimiento y cómo no siempre es patológico. Resume que el envejecimiento no implica deterioro, sino cambio y adaptación. Además, la plasticidad neuronal permite compensar la acumulación de años a través de mecanismos como la remielinización y la ramificación axonal. Recomienda no preocuparse sino ocuparse cuidando la salud a través de una dieta sana, ejercicio, evitar hábitos tóxicos y mantener la actividad intelectual con entrenamiento cognitivo de
Programa de actualizacion en demencias 2013Dario Yac
Este documento describe un programa de actualización en demencias organizado por el Grupo de Trabajo de Neurología del Comportamiento y Neurociencias Cognitivas. El programa consta de 8 módulos que se llevarán a cabo entre marzo y noviembre de 2013 con el objetivo de establecer consensos sobre la detección, evaluación, diagnóstico y tratamiento de las demencias. Cada módulo abarcará diversos temas relacionados con las demencias a través de clases teórico-prácticas. El programa está dirig
Este documento presenta un programa de capacitación sobre el manejo de pacientes con enfermedad de Alzheimer y otros trastornos cognitivos, dictado por el departamento de medicina SirEN. El programa dura 3 meses, con clases quincenales de 3 horas que abordan temas como los problemas cognitivos y de conducta en las demencias, así como estrategias para mejorar la calidad de vida de los pacientes y reducir la sobrecarga en los cuidadores. El objetivo es brindar herramientas a familiares y cuidadores sobre cómo manejar a los pacientes.
Bateria cognitiva breve en consultorio para npsDario Yac
Este documento presenta una batería cognitiva breve para evaluar el estado mental de pacientes en un consultorio. Incluye instrumentos para medir el rendimiento cognitivo como el Mini Mental State Examination y pruebas de atención, lenguaje y visoconstrucción. También incluye escalas para medir síntomas depresivos y determinar el nivel de demencia. Explica cómo administrar y puntuar algunas de las pruebas como el Test del Reloj y los Tests Seriales Gráficos.
El documento resume los tipos de olvidos normales y patológicos. Los olvidos benignos son olvidos de detalles poco importantes y son parte del envejecimiento normal, mientras que los olvidos patológicos involucran detalles más significativos y son motivo de preocupación para la familia, requiriendo una evaluación médica.
El documento presenta una galería de fotos relacionadas con el Día Internacional del Alzheimer, incluyendo fotos del Laboratorio de Investigación de la Memoria H Zubizarreta del año 2011 y fotos de la finalización de un curso para familiares de pacientes con demencia en el SIREN-CEMIC en 2012.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
2. Lopez et al. Page 2
Introduction
The improvement in life expectancy in practically every population around the world has led
NIH-PA Author Manuscript
the prevalence of Alzheimer’s disease to rise to epidemic proportions. It is estimated that 6–
7% of the individuals aged above 65 are affected, and Alzheimer’s disease represents 80%
of the dementia in this age group [1]; approximately 45% of the population aged above 85
have dementia [2]. Therefore, there are continuing efforts to better understand the
physiopathology of the disease and to develop therapies, for which it is essential to have
accurate and reliable clinical diagnoses.
As the search for useful diagnostic criteria moves towards the earliest manifestations of the
disease, it is increasingly important to explicitly distinguish between the neuropathological
disease – in this case Alzheimer’s disease –and its clinical manifestation (i.e. mild cognitive
impairment, dementia). Thus, the goal of the clinical criteria has been to maximize the
likelihood of identifying the pathological disease. This is critical to bear in mind, and to
recall that it has only been in the past 10–15 years that increasingly valid biomarkers for
Alzheimer’s disease have been developed.
During the past 30 years specific diagnostic criteria for Alzheimer’s disease have allowed
researchers to conduct pathological and clinical studies, and to compare incidence and
prevalence of dementia across multiple populations. Here we will discuss the evolution of
NIH-PA Author Manuscript
the clinical diagnosis of Alzheimer’s disease, especially the newly published criteria that
incorporate the use of biomarkers [3•].
Dementia
The first step in the diagnostic process of Alzheimer’s disease is to determine whether a
patient is actually demented. Although the syndrome of dementia has been described in
medical writings for centuries [4], at the time that Alzheimer described his case, the concept
of dementia involved behavioral and cognitive symptoms [5], and there was an emphasis on
nondegenerative causes (e.g. neurosyphilis). Over time, the central component of the
syndrome shifted towards cognitive symptoms, and the presumed cause evolved primarily
from nondegenerative diseases to atherosclerosis to neurodegeneration, and to a better
appreciation of the variety of pathologies that result in dementia [6].
Over the past 30 years, the bases of the cognitive syndrome of dementia have been driven by
the criteria proposed by the Diagnostic and Statistical Manual of Mental Disorders (DSM)
[7–10] (see Table 1); for the diagnosis of dementia there must be impairments in memory
and one additional cognitive domain. These cognitive deficits can cause significant
impairment in social or occupational functioning, and represent a significant decline from
NIH-PA Author Manuscript
previous levels of functioning. These DSM criteria are still being used in clinical practice
and research, although it is expected that there will be major modifications in the fifth
edition of the manual in 2013.
The International Classification of Disease (ICD-10) has a more strict definition for
dementia, requiring that memory and abstract thinking, judgement and problem solving all
are impaired, as well as one additional cognitive domain. Although these criteria have a high
specificity for dementia, they have low sensitivity because cases with mild disease are
missed. For example, in one study, the prevalence of dementia by DSM-IV was 13.7%,
whereas using ICD-10 it was only 3.1% [11].
Because not all dementia patients experience memory deficits as the initial symptom, it
seems reasonable that the definition of dementia should be less restrictive [12]. For example,
since 1984, the Alzheimer’s Disease Research Center at the University of Pittsburgh has
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
3. Lopez et al. Page 3
required impairments in two cognitive domains for the diagnosis of dementia, but these do
not have to include memory functions [13]. Using these criteria, we have a sensitivity of
98% and specificity of 88% relative to autopsy [13]. The recently developed National
NIH-PA Author Manuscript
Institute on Aging – Alzheimer’s Association (NIA-AA) criteria for all-cause dementia takes
a similar approach requiring deficits in any two of the following domains: memory,
judgement/problem-solving, visuospatial, language, and behavior (e.g. agitation) [3•].
Dementia and Alzheimer’s disease
Although the memory-centric DSM criteria seemed the perfect fit for the diagnosis of
Alzheimer’s disease, they lack sensitivity for Alzheimer’s disease syndromes [14–16] and
other dementias (e.g. frontotemporal) that do not present with memory deficits [17]. Even
Alzheimer’s disease cases without focal cognitive deficits can have a relative preservation of
their memory functions [18]; 7% of the Alzheimer’s disease cases can have normal verbal
and nonverbal memory, and 6% can have normal verbal memory with abnormal nonverbal
memory (see Fig. 1). This point is particularly important for clinicians and epidemiologists
as it points out the diagnostic problems when only verbal memory measures are used for
diagnosis.
Evolution of the diagnostic criteria for Alzheimer’s disease
The concept of the chronic organic brain syndrome codified in the DSM in 1952 [19] and
NIH-PA Author Manuscript
DSM-II in 1968 [20] evolved to current criteria for dementia and Alzheimer’s disease in the
third [7] and subsequent editions (DSM-III-R, DSM-IV and DSM-IV-TR) [8–10], and to the
1984 NINCDS-ADRDA clinical criteria [21]. What was critical about these latter criteria,
and is often forgotten, is that they ranked the diagnosis in terms of the certainty that the
dementia actually was caused by Alzheimer’s disease pathology. The grade of certainty
‘Definite Alzheimer’s disease’ was reserved for cases with neuropathological confirmation
(usually at autopsy). ‘Probable Alzheimer’s disease’ was the term used to describe the
clinical syndrome most likely expected in the context of Alzheimer’s disease, whereas
‘Possible Alzheimer’s disease’ was used when the patient had the core clinical symptoms for
Alzheimer’s disease but there was evidence of other disease processes that in and of
themselves could account for the cognitive deficits.
As the clinical criteria for Alzheimer’s disease become more specific, investigators began to
test the validity of these multiple research diagnostic criteria. The sensitivity of the clinical
diagnosis of Alzheimer’s disease tended to be higher when more detailed clinical criteria
were used, and when the study was conducted in referral clinics [13,22–38] compared to
population [39–41] or hospital-based studies [42–44] (see Table 2). However, the increased
knowledge of the Alzheimer’s disease phenotype and the introduction of clinical criteria for
NIH-PA Author Manuscript
other dementia syndromes in the 1990s [45–50] resulted in an increase in the accuracy of the
diagnosis of Alzheimer’s disease. Although the sensitivity of the clinical diagnosis for
Alzheimer’s disease improved after 1990, the specificity improved dramatically (Table 2).
One study simultaneously tested the diagnostic criteria for neurodegenerative dementias
[Alzheimer’s disease, progressive supranuclear palsy, Lewy body dementia (LBD),
frontotemporal dementia (FTD)], and found good sensitivity and specificity for all except
LBD (low sensitivity and high specificity) (see Fig. 2) [51]. This was also reflected in large
longitudinal series; for example, the specificity for Alzheimer’s disease at the ADRC of
Pittsburgh rose to 88% in the 1990s [13] (Fig. 3).
Revised NINCDS-ADRDA criteria for probable Alzheimer’s disease
The increased knowledge of the natural history of Alzheimer’s disease, the development of
positive bio-markers, and the need to better characterize Alzheimer’s disease patients in the
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
4. Lopez et al. Page 4
earliest, even predementia stage led to a proposed modification of the criteria for probable
Alzheimer’s disease [52]. The proposed criteria require the presence of gradual and
progressive change in memory function, characterized by deficits in memory storage [53].
NIH-PA Author Manuscript
These criteria elevated the importance of biomarkers and genotypes to support the diagnosis
of Alzheimer’s disease by requiring that the Alzheimer’s disease phenoptype should include
one of the following: atrophy in the medial temporal lobe structures in the MRI, an
abnormal cerebrospinal fluid (CSF) study, an ‘Alzheimer’s disease pattern’ on positron
emission tomography (PET) studies [i.e. 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) or with
amyloid ligands], or the presence of an autosomal dominant mutation in the immediate
family.
These revised criteria also addressed the issue of prodromal or preclinical Alzheimer’s
disease; these mildly affected patients can be classified as probable Alzheimer’s disease
when they have an isolated memory deficit and at least one of the biomarkers described
above. The term ‘definite’ Alzheimer’s disease was again used for patients with
pathologically confirmed Alzheimer’s disease, and those living patients with Alzheimer’s
disease clinical symptoms and genetic evidence of Alzheimer’s disease (mutations in
chromosome 1, 14, or 21).
NIA-AA criteria for Alzheimer’s disease
NIH-PA Author Manuscript
Following the publication of the revised criteria for probable Alzheimer’s disease, the NIA
and the Alzheimer’s Association organized a workgroup to revise the entire NINCDS-
ADRDA criteria by integrating advances in the knowledge of the disease into the decision
tree, and to provide general practitioners with the tools to make the diagnosis at the bedside.
These NIA-AA criteria retained the degrees of certainty that the clinical syndrome
represented the neurodegenerative condition, that is probable and possible Alzheimer’s
disease (see Table 3).
The NIA-AA criteria for dementia require deficits in two cognitive domains, not necessarily
memory, and they also included a description of each domain for use in clinical practice.
This is an improvement over the NINCDS-ADRDA criteria that stated that the dementia
syndrome was present only when patients had deficits in two cognitive domains, but they
were less clear whether memory had to be affected. This type of broader definition of
dementia provides higher sensitivity and specificity for the Alzheimer’s disease diagnosis
[13].
The inclusion of biomarkers in the criteria brings to the classification of Alzheimer’s disease
aspects of its pathophysiology (see also [52]). Low amyloid (A)β-42 and high tau protein
levels in CSF [54,55], decreased cerebral metabolism [56], decreased mesial temporal and
NIH-PA Author Manuscript
parietal lobe volumes [57,58], and increased amyloid deposition in the brain with PET
amyloid ligands [59] have been replicated in multiple studies. It is believed that these
biomarkers measure two aspects of the disease: amyloid deposition (i.e. low CSF Aβ-42
levels and positive PET amyloid imaging), and neuronal damage (i.e. high tau protein levels
in CSF, decreased cerebral glucose metabolism, and disproportionate temporal/parietal
atrophy). However, there is still a lack of standardization of the technologies and limited
access to them by the medical community. For example, there is a large standard deviation
in CSF tau and Aβ-42 levels in cases with definite Alzheimer’s disease [60], and whereas
volumetric MRI studies have consistently showed that specific areas of the brain are affected
in Alzheimer’s disease and mild cognitive impairment (MCI) [61], visual MRI ratings have
shown poor accuracy and inter-rater reliability [62] (cf. [63]). Therefore, biomarkers are, at
present, most useful for research or clinical trials, or in limited clinical circumstances.
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
5. Lopez et al. Page 5
The original NINCDS-ADRDA criteria assumed that Alzheimer’s disease occurred in the
40–90 years age range and that patients with age of onset below 65 should be considered a
separate subgroup – both of these were rejected by the new criteria. Considering age as a
NIH-PA Author Manuscript
part of the diagnostic criteria had been a holdover from the 1960s–1970s when Alzheimer’s
disease was a presenile syndrome and dementia after age 65 was referred to as senile
dementia of Alzheimer’s type, and there was little knowledge about the prevalence of
dementia in the old-old (age >85). It is now clear that the neuropathology and clinical
presentation of Alzheimer’s disease is unrelated to age [64,65], and that the central
underlying pathology is similar in familial cases with early (age <40 years) and late-onset
Alzheimer’s disease [66,67].
Possible Alzheimer’s disease
The term ‘possible Alzheimer’s disease’ was used for patients with atypical presentation or
clinical course, when another disease process that could cause cognitive disorders was
present, or when there was present a progressive deficit in a single cognitive domain [21].
The NIA-AA criteria have redefined this classification, and considered possible Alzheimer’s
disease when the patient has sudden onset of symptoms; insufficient historical detail to
document progression of symptoms; evidence of concomitant disorders; or, medication use
that can affect cognition. It should be noted that possible Alzheimer’s disease can evolve to
probable Alzheimer’s disease if the concomitant condition resolves in the context of
NIH-PA Author Manuscript
progressive dementia.
The NIA-AA criteria also recognize that two conditions that can cause dementia may
coexist. Patients with core Alzheimer’s disease features may have signs and symptoms of
other neurodegenerative processes (e.g. LBD), and patients with dementia syndomes (e.g.
FTD) can have the biomarkers for Alzheimer’s disease. This approach is used successfully
in research clinics where patients were classified primarily based on the NINCDS-ADRDA
clinical criteria for Alzheimer’s disease, and secondarily according to the specific diagnostic
criteria for other disease processes (e.g. DLB) [68].
The original NINDCS-ADRDA criteria classified patients with deficits in a single cognitive
domain as possible Alzheimer’s disease; this has been revised by the NIA-AA criteria, and
these patients are now classified as MCI. However, these new criteria recommend that when
there is significant interference in the ability to function, clinicians should use their own
judgment to distinguish MCI from a dementia syndrome when only a single cognitive
domain affected. This change in the use of possible Alzheimer’s disease has important
conceptual implications, perhaps the most important of which is that it assumes that MCI is
preclinical Alzheimer’s disease.
NIH-PA Author Manuscript
Mild cognitive impairment
As patients progress to dementia they go through a state of mild cognitive deficit, and
multiple diagnostic criteria have been proposed to characterize this transitional state [69–
74]. The MCI with memory loss is the most similar to Alzheimer’s disease, and these
patients are the most likely to develop Alzheimer’s disease [75]. However, epidemiological
studies have shown that the ‘pure’ MCI-amnestic-type (i.e. idiopathic amnesia) has a low
prevalence in the general population compared to those patients with a much wider range of
cognitive impairments [76,77], and MCI patients without memory deficits can also progress
to Alzheimer’s disease [78]. The initial memory-based criteria for MCI [75] were expanded
in 2004 to include all the possible cognitive manifestations of the syndrome (see Table 4)
[79,80].
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
6. Lopez et al. Page 6
The NIA-AA criteria for MCI were developed primarily to identify a syndrome that had a
high likelihood of being caused by Alzheimer’s disease pathology [81•] and are reminiscent
of what had been referred to as ‘very mild Alzheimer’s disease’ [82,83]. These criteria state
NIH-PA Author Manuscript
that there must be evidence of impairment in one or more cognitive domains, typically
including memory, and there are groupings only for patients with memory impaired or
memory + other cognitive domains. The criteria maximize the likelihood that the syndrome
is associated with Alzheimer’s disease by explicitly ruling out vascular, traumatic, or other
causes of mild central nevous system dysfunction. However, given that all Alzheimer’s
disease patients do not have memory loss at initial presentation, and that memory loss may
not be the most severe deficit, this is a limiting aspect of the criteria.
The foundation of the recent NIA-AA MCI guidelines is the core clinical criteria (see Table
4). The general structure retains that established over the past 10 years but clarifies a few
points to reflect the evolution of the MCI paradigm. Included in this are: the emphasis that a
subjective cognitive complaint or change can come from the patient, an informant or the
physician observing the patient; independence in functioning remains necessary but
examples of mild changes in more ‘complex functional tasks’ that may be affected are
provided; impairment in one or more cognitive domains, although episodic memory is
emphasized as being the most commonly associated with the development of Alzheimer’s
disease. Additional support for the diagnosis of MCI is provided when there is evidence of a
decline on serial testing.
NIH-PA Author Manuscript
Whereas the identification of the ‘pure Alzheimer’s disease’ form of MCI is critical for
research studies and clinical trials, the reality is that MCI patients with multiple
comorbidities are the most common in clinical practice and they also progress to
Alzheimer’s disease at the same rate as those without comorbidities [78]. Thus, even in the
presence of a disease process that could explain the MCI syndrome, there is frequently an
underlying neurodegenerative process that will eventually lead to the dementia symptoms.
In this case the biomarkers have a critical role in identifying Alzheimer’s disease patients in
the context of other pathologies, and thus improving treatment and management.
The use of biomarkers in the classification of MCI not only supports the presence of the
Alzheimer’s disease pathology, but also increases the likelihood that the progression to
dementia will occur within a relatively short period of time [84–87]. The NIA-AA criteria
graded the certainty that the MCI is due to Alzheimer’s disease as follows: high likelihood:
when both beta amyloid and neuronal damage biomarkers are present; intermediate
likelihood: when the core clinical symptoms are present and there is a single positive
biomarker, either amyloid deposition or neuronal damage; and unlikely due to Alzheimer’s
disease: neither types of biomarkers are positive. However, the authors cautioned against the
NIH-PA Author Manuscript
use of combination biomarkers until more experience is gained in this respect. Indeed, the
Alzheimer’s Disease Neuroimaging Initiative found that over a short term, single marker
models were as effective as multiple marker models, and their accuracy was only 64% [88].
Preclinical Alzheimer’s disease
The pathology of Alzheimer’s disease likely starts decades before the onset of the clinical
syndrome, and cognitively normal elderly individuals who later develop Alzheimer’s disease
have a different cognitive performance than those who do not [89,90]. Pathological [91,92]
and amyloid imaging studies [93,94] find cognitively normal individuals with Alzheimer’s
disease neuropathology. The NIA-AA work group position is that Alzheimer’s disease is a
pathological–clinical continuum that starts with the amyloid deposition in cognitively
normal individuals and gradually progresses to clinical dementia [95•]. Therefore, three
disease stages were proposed: stage 1: normal cognition with positive cerebral amyloidosis
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
7. Lopez et al. Page 7
by CSF or amyloid ligand studies, and with normal markers of neuronal damage; stage 2:
normal cognition with cerebral amyloidosis and markers of downstream neurodegeneration;
and stage 3: subtle cognitive change with cerebral amyloidosis and markers of
NIH-PA Author Manuscript
neurodegeneration. The latter stage includes individuals who are in the borderzone between
normal and MCI; ‘not normal’ and ‘not MCI’.
There are limitations in the preclinical staging because the cause of Alzheimer’s disease is
complex, and the majority of the existing data are from cross-sectional or short-term follow-
up studies. It is still not clear whether there is a single sequence of events in the pathological
cascade during the preclinical phase. The central pathological event appears to be amyloid
deposition, and this should precede damage to neurons. However, cognitively normal
individuals aged 50–65, APOE-4+, have decreased cerebral metabolism in the brain regions
usually affected by Alzheimer’s disease [96]. Thus, amyloid deposition and neuronal
damage can progress in parallel, although the critical multimodal longitudinal data are
lacking.
Conclusion
There have been significant advances in the understanding of the Alzheimer’s disease
phenotype. The incorporation of biomarkers to clinical diagnostic criteria is a major step
forward in research and clinical practice. However, studies to validate the new criteria will
NIH-PA Author Manuscript
be difficult to perform due to the need for large numbers of individuals with biomarkers, and
waiting for autopsy data. Nevertheless, small studies have been conducted, and a recent
radiological–pathological study conducted in 26 institutionalized dementia patients showed
that an amyloid ligand had 96% accuracy for Alzheimer’s disease [97].
It is not clear whether there is a single or multiple underlying causes of Alzheimer’s disease,
and consequently a single specific biomarker may not be possible. However, the clinical
observations conducted over the past 30 years have led to the development of clinical
criteria that can detect the underlying disease with high accuracy. The inclusion of
biomarkers and the characterization of a prodromal Alzheimer’s disease phenotype represent
an important step forward in the new conceptualization of the diagnosis of the disease. The
strict clinical definition makes these criteria suitable for research purposes in which
homogeneous groups are needed. By including these biomarkers, we can constrain the
patients who are included in clinical trials, and maximize the likelihood that we are studying
only Alzheimer’s disease pathology. However, with the increased reliance on such
biological tools, it is critical to remember the admonition of German Berrios [6]:
So, paradoxically, the more that scientific detail has accumulated on Alzheimer’s
disease, the more elusive the ‘illness’ has become. In an effort to make it a separate
NIH-PA Author Manuscript
entity, the creators of the disease may have narrowed its clinical boundaries unduly,
so that current research workers are trapped in the vicious circle of only finding
what they themselves put there in the first place’ (p. 7).
Acknowledgments
Preparation of this manuscript was supported, in part, by funds from the National Institute on Aging (AG20098 and
AG05133). M.R. is supported by a grant from Fundación Caja Madrid (Spain).
References and recommended reading
Papers of particular interest, published within the annual period of review, have been
highlighted as:
• of special interest
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
8. Lopez et al. Page 8
•• of outstanding interest
Additional references related to this topic can also be found in the Current World Literature
section in this issue (pp. 653–654).
NIH-PA Author Manuscript
1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study.
Lancet. 2005; 366:2112–2117. [PubMed: 16360788]
2. Fitzpatrick AL, Kuller LH, Ives D, et al. Incidence and prevalence of dementia in the
Cardiovascular Health Study. J Am Geriatr Soc. 2004; 52:195–204. [PubMed: 14728627]
3•. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s
disease: recommendations from the National Institute on Aging and the Alzheimer’s Association
workgroup. Alzheimers Dement. 2011; 7:263–269. New clinical criteria for all-cause dementia
and for Alzheimer’s disease. These criteria incorporate CSF and radiological biomarkers to
support the diagnosis of Alzheimer’s disease. [PubMed: 21514250]
4. Berrios, GE. The history of mental symptoms. Descriptive psychopathology since the nineteenth
century. Cambridge: Cambridge University Press; 1996.
5. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Zeits f Psychiat. 1907; 64:146–
148.
6. Berrios, GE.; Freeman, HL. Alzheimer and the dementias (Eponymists in Medicine). London: Royal
Society of Medicine Services Ltd; 1991.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3. New
York: APA; 1980. (DSM-III)
NIH-PA Author Manuscript
8. American Psychiatric Association. Diagnostic and statistical manual on mental disorders. 3.
Washington, DC: American Psychiatric Press; 1987. Revised (DSM-III-R)
9. American Psychiatric Association. Diagnostic and statistic manual of mental disorders. 4.
Washington, DC: American Psychiatric Association; 1994. (DSM-IV)
10. American Psychiatric Association. Diagnostic and Statistic Manual of Mental Disorders. 4.
Washington, DC: American Psychiatric Association; 2000. Text Revision (DSM-IV-TR)
11. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the
prevalence of dementia. N Engl J Med. 1997; 337:1667–1674. [PubMed: 9385127]
12. Becker JT, Boller F, Lopez OL, et al. The natural history of Alzheimer’s disease: description of
study cohort and accuracy of diagnosis. Arch Neurol. 1994; 51:585–594. [PubMed: 8198470]
13. Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer’s
disease over the last two decades. I Neurology. 2000; 55:1854–1862.
14. Hof PR, Archin N, Osmand AP, et al. Posterior cortical atrophy in Alzheimer’s disease: analysis of
a new case and re-evaluation of a historical report. Acta Neuropathol (Berl). 1993; 86:215–223.
[PubMed: 8213079]
15. Johnson JK, Head E, Kim R, et al. Clinical and pathological evidence for a frontal variant of
Alzheimer disease. Arch Neurol. 1999; 56:1233–1239. [PubMed: 10520939]
16. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer’s disease. Brain. 2007;
NIH-PA Author Manuscript
130 (Pt 10):2636–2645. [PubMed: 17898010]
17. Neary D, Snowden J. Fronto-temporal dementia: nosology, neuropsychology, and neuropathology.
Brain Cogn. 1996; 31:176–187. [PubMed: 8811995]
18. Becker JT, Lopez OL, Wess J. Material specific memory loss in probable Alzheimer’s disease. J
Neurol Neurosurg Psychiatry. 1992; 55:1177–1181. [PubMed: 1479397]
19. American Psychiatric Association. Diagnostic and statistic manual of mental disorders.
Washington, DC: American Psychiatric Association; 1952.
20. American Psychiatric Association. Diagnostic and statistic manual of mental disorders. 2.
Washington, DC: American Psychiatric Association; 1968. (DSM-II)
21. McKhann G, Drachman DA, Folstein MF, et al. Clinical diagnosis of Alzheimer’s disease: Report
of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human
Services Task Force on Alzheimer’s disease. Neurology. 1984; 34:939–944. [PubMed: 6610841]
22. Burns A, Luthert P, Levy R, et al. Accuracy of clinical diagnosis of Alzheimer’s disease. Br Med J.
1990; 301:1026. [PubMed: 2249050]
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
9. Lopez et al. Page 9
23. Boller F, Lopez OL, Moossy J. Diagnosis of dementia: clinicopathological correlations.
Neurology. 1989; 39:76–79. [PubMed: 2642615]
24. Blacker D, Albert MS, Bassett SS, et al. Reliability and validity of NINCDS-ADRDA criteria for
NIH-PA Author Manuscript
Alzheimer’s disease. Arch Neurol. 1994; 51:1198–1204. [PubMed: 7986174]
25. Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia
disorders in the elderly. J Neurol Sci. 1990; 95:239–258. [PubMed: 2358819]
26. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer’s
disease and related dementias. Arch Neurol. 1994; 51:888–895. [PubMed: 8080388]
27. Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer’s disease: autopsy
neuropathological results in 150 cases. Ann Neurol. 1988; 24:50–56. [PubMed: 3415200]
28. Kukull WA, Larson EB, Reifler BV, et al. The validity of 3 clinical diagnostic criteria for
Alzheimer’s disease. Neurology. 1990; 40:1364–1369. [PubMed: 2392219]
29. Mendez MF, Mastri AR, Sung JH, et al. Neuropathologically confirmed Alzheimer’s disease:
clinical diagnoses in 394 cases. J Geriatr Psychiatry Neurol. 1991; 4:26–29. [PubMed: 2054048]
30. Wade JP, Mirsen TR, Hachinski VC, et al. The clinical diagnosis of Alzheimer’s disease. Arch
Neurol. 1987; 44:24–29. [PubMed: 3800717]
31. Kosunen O, Soininen H, Paljarvi L, et al. Diagnostic accuracy of Alzheimer’s disease: a
neuropathological study. Acta Neuropathol (Berl). 1996; 91:185–193. [PubMed: 8787153]
32. Victoroff J, Mack WJ, Lyness SA, Chui HC. Multicenter clinicopathological correlation in
dementia. Am J Psychiatry. 1995; 152:1476–1484. [PubMed: 7573587]
33. Kazee AM, Eskin TA, Lapham LW, et al. Clinicopathologic correlates in Alzheimer disease:
NIH-PA Author Manuscript
assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord. 1993;
7:152–164. [PubMed: 8217089]
34. Gearing M, Mirra SS, Hedreen JC, et al. The Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s
disease. Neurology. 1995; 45:461–466. [PubMed: 7898697]
35. Jobst KA, Lin PD, Barnetson PD, Shepstone BJ. Accurate prediction of histologically confirmed
Alzheimer’s disease and the differential diagnosis of dementia: the use on NINCDS-ADRDA and
DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Int
Psychogeriatrics. 1998; 10:271–302.
36. Nagy Z, Esiri MM, Hindley NJ, et al. Accuracy of clinical operational diagnostic criteria for
Alzheimer’s disease in relation to different pathological diagnostic protocols. Dement Geriatr
Cogn Disord. 1998; 9:219–226. [PubMed: 9681644]
37. Massoud F, Devi G, Stern Y, et al. A clinicopathological comparison of community-based and
clinic-based cohorts of patients with dementia. Arch Neurol. 1999; 56:1368–1373. [PubMed:
10555657]
38. Hogervorst E, Bandelow S, Combrinck M, et al. The validity and reliability of 6 sets of clinical
criteria to classify Alzheimer’s disease and vascular dementia in cases confirmed postmortem:
added value of a decision tree approach. Dement Geriatr Cogn Disord. 2003; 16:170–180.
NIH-PA Author Manuscript
[PubMed: 12826744]
39. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer’s
disease, vascular dementia, and dementia with Lewy bodies. Br J Psychiatry. 1999; 174:45–50.
[PubMed: 10211150]
40. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer’s disease in
a community-based case series. J Am Geriatr Soc. 1999; 47:564–569. [PubMed: 10323650]
41. Petrovich H, White LR, Ross GW, et al. Accuracy of clinical criteria for AD in the Honolulu-Asia
Aging Study, a population-based study. Neurology. 2001; 57:226–234. [PubMed: 11468306]
42. Alafuzoff I, Igbal K, Friden H, et al. Histopathological criteria for progressive dementia disorders:
clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol
(Berl). 1987; 74:209–225. [PubMed: 3673513]
43. Todorov A, Go R, Constantinidis J, Elston R. Specificity of the clinical diagnosis of dementia. J
Neurol Sci. 1975; 26:81–98. [PubMed: 1159460]
44. Molsa P, Paljarvi L, Rinne J, et al. Validity of clinical diagnosis in dementia. J Neurol Neurosurg
Psychiatry. 1985; 48:1085–1090. [PubMed: 4078573]
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
10. Lopez et al. Page 10
45. Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia.
J Neurol Neurosurg Psychiatry. 1994; 57:416–418. [PubMed: 8163988]
46. McKeith IG, Fairbairn AF, Perry RH. Clinical diagnostic criteria for Lewy body dementia.
NIH-PA Author Manuscript
Dementia. 1992; 3:251–252.
47. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive
supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP
International Workshop. Neurology. 1996; 47:1–9. [PubMed: 8710059]
48. Chui HC, Victoroff JI, Margolin D, et al. Criteria for the diagnosis of ischemic vascular dementia
proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers.
Neurology. 1992; 42:473–480. [PubMed: 1549205]
49. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research
studies: report of the NINDS-AIREN International Workshop. Neurology. 1993; 43:250–260.
[PubMed: 8094895]
50. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with
Parkinson’s disease. Mov Disord. 2000; 22:1689–1707. [PubMed: 17542011]
51. Lopez OL, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of
neurodegenerative dementias. Neurology. 1999; 53:1292–1299. [PubMed: 10522887]
52. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease:
revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6:734–746. [PubMed: 17616482]
53. Delis DC, Wetter SR, Jacobson MW, et al. Recall discriminability: utility of a new CVLT-II
measure in the differential diagnosis of dementia. J Int Neuropsychol Soc. 2005; 11:708–715.
NIH-PA Author Manuscript
[PubMed: 16248906]
54. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a
biochemical marker for Alzheimer’s disease: a community based follow up study. J Neurol
Neurosurg Psychiatry. 1998; 64:298–305. [PubMed: 9527138]
55. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in
the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch
Neurol. 1998; 55:937–945. [PubMed: 9678311]
56. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of
dementia: regional brain metabolism and long-term outcome. J Am Med Assoc. 2001; 286:2120–
2127.
57. Thompson PM, Moussai J, Zohoori S, et al. Cortical variability and asymmetry in normal aging
and Alzheimer’s disease. Cereb Cortex. 1998; 8:492–509. [PubMed: 9758213]
58. Jack CR, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very
mild Alzheimer’s disease. Neurology. 1997; 49:786–794. [PubMed: 9305341]
59. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with
Pittsburgh Compond-B. Ann Neurol. 2004; 55:306–319. [PubMed: 14991808]
60. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid. How well do these
biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003; 60:1696–1702.
NIH-PA Author Manuscript
[PubMed: 14676043]
61. Thompson, PM.; Hayashi, KM.; Dutton, RA., et al. Tracking Alzheimer’s disease. In: De Leon,
MJ.; Federoff, H.; Hirsch, J., et al., editors. Proceedings of the New York Academy of Sciences.
2006. Special Issue on Imaging and the Aging Brain
62. Raji CA, Lee C, Lopez OL, et al. Initial experience in using continuous arterial spin-labeled MR
imaging for early detection of Alzheimer disease. AJNR Am J Neuroradiol. 2010; 31:847–855.
[PubMed: 20075093]
63. Duara R, Loewenstein DA, Potter E, et al. Medial temporal lobe atrophy on MRI scans and the
diagnosis of Alzheimer disease. Neurology. 2008; 71:1986–1992. [PubMed: 19064880]
64. Terry RD, Davies P. Dementia of the Alzheimer type. Annu Rev Neurosci. 1980; 3:77–95.
[PubMed: 6251745]
65. Sulkava R. Alzheimer’s disease and senile dementia of Alzheimer type. Acta Neurol Scand. 1982;
26:81–98.
66. Shepherd C, McCann H, Halliday GM. Variations in the neuropathology of familial Alzheimer’s
disease. Acta Neuropathol. 2009; 118:37–52. [PubMed: 19306098]
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
11. Lopez et al. Page 11
67. Klunk W, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1
mutation carriers from two unrelated pedigrees. J Neurosci. 2007; 27:6174–6184. [PubMed:
17553989]
NIH-PA Author Manuscript
68. Lopez OL, Becker JT, Kaufer DI, et al. Research evaluation and prospective diagnosis of dementia
with Lewy bodies. Arch Neurol. 2002; 59:43–46. [PubMed: 11790229]
69. Kral VA. Senescent forgetfullness: benign and malignant. Br Med J. 1962; 304:5–6.
70. Crook TH, Bartus RT, Ferris SH, et al. Age-associated memory impairment: proposed diagnostic
criteria and measures of clinical change. Report of a National Institute of Mental Health Work
Group. Dev Neuropsychol. 1986; 2:261–276.
71. Blackford RC, LaRue A. Criteria for diagnosing age associated memory impairment: proposed
improvements from the field. Dev Neuropsychol. 1989; 5:295–306.
72. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia.
Neurology. 1991; 41:1006–1009. [PubMed: 2067629]
73. Graham JE, Rockwood K, Beattie EL. Prevalence and severity of cognitive impairment with and
without dementia in an elderly population. Lancet. 1997; 349:1793–1796. [PubMed: 9269213]
74. Levy R. Aging-associated cognitive decline. From the Aging-Associated Cognitive Decline
Working Party. Int Psychogeriatr. 1994; 6:63–68. [PubMed: 8054494]
75. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and
outcome. Arch Neurol. 1999; 56:303–308. [PubMed: 10190820]
76. Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive
impairment in the Cardiovascular Health Study Cognitive Study Part 1. Arch Neurology. 2003;
NIH-PA Author Manuscript
60:1385–1389.
77. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an
epidemiologic study. Neurology. 2004; 63:115–121. [PubMed: 15249620]
78. Lopez OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the
Cardiovascular Health Study. Arch Neurol. 2007; 64:416–420. [PubMed: 17353386]
79. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256:183–194.
[PubMed: 15324362]
80. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies,
towards a consensus – report of the International Working Group on Mild Cognitive Impairment. J
Intern Med. 2004; 256:240–246. [PubMed: 15324367]
81•. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to
Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s
Association workgroup. Alzheimers Dement. 2011; 7:270–279. These are the new clinical
criteria for the mild cognitive impairment due to Alzheimer’s disease. These criteria included
memory and memory and other cognitive domain forms of mild cognitive impairment and are
supported by the presence of biomarkers. [PubMed: 21514249]
82. desRosiers G, Hodges JR, Berrios G. The neuropsychological differentiation of patients with very
mild Alzheimer’s disease and/or major depression. J Am Geriatr Soc. 1995; 43:1256–1263.
NIH-PA Author Manuscript
[PubMed: 7594160]
83. Perry RJ, Hodges JR. Fate of patients with questionable (very mild) Alzheimer’s disease:
longitudinal profiles of individual subjects’ decline. Dement Geriatr Cogn Disord. 2000; 11:342–
349. [PubMed: 11044780]
84. Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer’s disease using the CSF
Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord.
2007; 23:316–320. [PubMed: 17374949]
85. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in
mild cognitive impairment. Neurology. 1999; 52:1397–1403. [PubMed: 10227624]
86. Chetelat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment. Can FDG-PET
predict who is to rapidly convert to Alzheimer’s disease? Neurology. 2003; 60:1374–1377.
[PubMed: 12707450]
87. Wolk DA, Price JC, Saxton J, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann
Neurol. 2009; 65:557–568. [PubMed: 19475670]
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
12. Lopez et al. Page 12
88. Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive
impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test
performance. Neurobiol Aging. [Epub ahead of print].
NIH-PA Author Manuscript
89. Kawas CH, Corrada MM, Brookmeyer R, et al. Visual memory predicts Alzheimer’s disease more
than a decade before diagnosis. Neurology. 2003; 60:1089–1093. [PubMed: 12682311]
90. Saxton J, Lopez OL, Ratcliff GR, et al. Preclinical Alzheimer disease. Neuropsychological test
performance 1. 5 to 8 years prior to dementia onset. Neurology. 2004; 63:2341–2347. [PubMed:
15623697]
91. Morris JC, Stornadt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in
‘normal’ aging: Evidence for presymptomatic and very mild Alzheimer’s disease. Neurology.
1996; 46:707–719. [PubMed: 8618671]
92. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without
cognitive impairment from two community-based studies. Neurology. 2006; 66:1837–1844.
[PubMed: 16801647]
93. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant
cognitive impairment among the elderly. Arch Neurol. 2008; 65:1509–1517. [PubMed: 19001171]
94. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential
antecedent marker of Alzheimer disease. Neurology. 2006; 67:446–452. [PubMed: 16894106]
95•. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s
disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association
workgroup. Alzheimers Dement. 2011; 7:280–292. These are recommendations oriented to
describe Alzheimer’s disease in its earliest stages, when the clinical symptoms are not evident
NIH-PA Author Manuscript
but the disease is present. [PubMed: 21514248]
96. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer’s disease in persons
homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996; 334:752–758.
[PubMed: 8592548]
97. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid
pathology. J Am Med Assoc. 2011; 305:275–283.
NIH-PA Author Manuscript
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
13. Lopez et al. Page 13
Key points
• The evolution of the clinical criteria for Alzheimer’s disease has improved
NIH-PA Author Manuscript
significantly the sensitivity and specificity for the disease.
• The use of biomarkers improves detection of the Alzheimer’s disease pathology
before the development of the symptoms of dementia.
• The use of biomarkers is limited to research studies and clinical trials at this
time.
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
14. Lopez et al. Page 14
NIH-PA Author Manuscript
Figure 1.
Material-specific memory loss in 194 patients with the diagnosis of probable Alzheimer’s
disease
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
15. Lopez et al. Page 15
NIH-PA Author Manuscript
Figure 2.
Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative
dementias
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
16. Lopez et al. Page 16
NIH-PA Author Manuscript
Figure 3.
Sensitivity and specificity for Alzheimer’s disease using standardized clinical criteria at the
Alzheimer’s Disease Research Center of Pittsburgh
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
17. Lopez et al. Page 17
Table 1
Cognitive features of different dementia criteria used for clinical practice and research
NIH-PA Author Manuscript
DSM-III (1980) to ADRC of
Impairments DSM-IV-TR (2001) ICD-10 (1994) NIA-AA (2010) Pittsburgh (1984)
Memory + one cognitive domain Yes
Memory + two domainsa Yesa,b
Two domains or more, not necessarily memory Yesc Yes
impaired
ADRC, Alzheimer’s Disease Research Center.
a
Memory (verbal + nonverbal) + abstract thinking, judgment and problem solving + other cognitive domain.
b
Behavioral symptoms strengthen the diagnosis.
c
One of the domains could be behavioral abnormalities.
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
18. Lopez et al. Page 18
Table 2
Sensitivity and specificity for Alzheimer’s disease before and after 1990a
NIH-PA Author Manuscript
Authors Clinical criteria Number of cases Sensitivity Specificity
Before 1990
Todorov et al. (1975) [43] Clinical diagnosis 726 43% 19%
Mölsa et al. (1985) [44] Clinical diagnosis 58 71% 73%
Alafuzoff et al. (1987) [42] DSM-III 55 63% N/A
Wade et al. (1987) [30] Standardized criteria 65 87% 78%
Joachim et al. (1988) [27] Standardized criteria 150 87% N/A
Boller et al. (1989) [23] NINCDS-ADRDA 54 95% 33%
After 1990
Kukul et al. (1990) [28] NINCDS-ADRDA 62 92% 65%
DSM-III 76% 80%
Jellinger et al. (1990) [25] NINCDS-ADRDA 675 85% N/A
Burns et al. (1990) [22] NINCDS-ADRDA 50 84% N/A
Mendez et al. (1991) [29] Clinical diagnosis 394 88% N/A
Kazee et al. (1993) [33] NINCDS-ADRDA 123 98% 69%
NIH-PA Author Manuscript
Galasko et al. (1994) [26] NINCDS-ADRDA 151 86% N/A
Blacker et al. (1994) [24] NINCDS-ADRDA 60 81% 73%
Gearing et al. (1995) [34] NINCDS-ADRDA 106 87% N/A
Kosunen et al. (1996) [31] NINCDS-ADRDA 56 96% N/A
Jobst et al. (1998) [35] NINCDS-ADRA 151 96% 61%
DSM-III-R 51% 97%
Nagy et al. (1998) [36] NINCDS-ADRA 73 98% 61%
Holmes et al. (1999) [39] NINCDS-ADRDA 80b 66% 75%
Lim et al. (1999) [40] NINCDS-ADRDA 134b 75% 54%
Massoud et al. (1999) [37] NINCDS-ADRDA 63 98% 84%
Lopez et al. (2000) [13] NINCDS-ADRDA 295 98% 88%
Petrovich et al. (2001) [41] NINCDS-ADRDA 79b 87% N/A
Hogervorst et al. (2003) [38] NINCDS-ADRDA 204 92% 69%
N/A, not available.
NIH-PA Author Manuscript
a
Clinicopathological studies with 50 or more patients.
b
Population-based study.
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
19. Lopez et al. Page 19
Table 3
Relevant aspects of the NINCDS-ADRDA and NIA-AA diagnostic criteria for Alzheimer’s disease
NIH-PA Author Manuscript
NINCDS-ADRDA (1984) NIA-AA (2011)
Dementia criteria Not provided Provides criteria for all-cause dementia
Probable AD
Dementia diagnosis Impairments in two cognitive domains based on Impairments in two cognitive domains, and
clinical exam and documented by cognitive testing [1] expands the definition on the nonmemory forms of
AD (language, visuospatial, executive) [1]
Onset and progression Progressive worsening of memory symptoms and Insidious onset and clear-cut history of worsening
other cognitive functions [1] of cognition by report or observation [1]
Comorbid systemic or Absence of systemic or neurological disorders that in Absence of cerebrovascular disease or other
neurological disorders and of themselves could account for the cognitive neurological, nonneurological comorbidities or use
deficits [1] of medication that could have substantial effect on
cognition [1]
Age Between ages 40 and 90 [1] No age limitation
Behavioral and neurological Altered pattern of behavior and mood-related Mood-related and behavioral symptoms are
symptoms disorders (e.g. depression), increased muscle tone, considered a ‘domain’ in the definition of dementia
myoclonus, gait disorders
Level of consciousness The diagnosis of AD cannot be made in patients with Symptoms cannot be explained by delirium or other
delirium, drowsiness, stupor/coma, or other major psychiatric disorder
abnormality that prevent adequate evaluation.
NIH-PA Author Manuscript
Laboratory test Normal lumbar puncture and blood tests. CT scan Not stated
normal or with atrophy
Biomarkers Not available in 1984 MRI, PET, and CSF studies. Any biomarker
positive increases the certainty of AD in patients
with probable AD. Recommended only for research
purposes or clinical trials
Familial forms Familial history of similar disorders, particularly if Evidence of a causative gene (APP, PSEN1, and
confirmed by autopsy supports the diagnosis of AD PSEN2) increases the likelihood of AD pathology.
The APOE-4 allele is not sufficiently specific to be
considered in this category
Possible AD
Comorbid conditions Presence of systemic or neurological disorders that in Meets clinical criteria for AD but there is
and of themselves could account for the cognitive cerebrovascular disease, or other neurological or
deficits, which is not considered to be the cause of the non-neurological comorbidities, or use of
dementia medication that could have substantial effect on
cognition
Atypical presentations Presence of variations in the presentation, onset, or Presence of atypical course, sudden onset, or there
clinical course is insufficient historical detail or documentation of
progressive decline
Single cognitive domain Presence of a single cognitive deficit in the absence of Replaced by MCI
other identifiable cause
NIH-PA Author Manuscript
Non-AD phenotype Not addressed At least two biomarker categories positive (Aβ
CSF, tau CSF, PET, or MRI) to support the
presence of underlying AD pathology
AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment.
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
20. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript
Table 4
Evolution of the construct of the MCI criteria
MCI: Petersen et al. NIA-AA: MCI due to Alzheimer’s
(1999) [75] MCI: Petersen (2004) [79] MCI: Winblad et al. (2004) [80] disease (2011) [81•]
Lopez et al.
Cognitive complaints By patient or informant By patient or informant By patient or informant By patient or informant
Memory deficits detected on Abnormal memory for Abnormal memory for age Abnormal memory for age Abnormal memory for age. Memory tests
testing age 1–1.5 SD below the norms
Other cognitive domains Normal Four subtypes: Three subtypes: Impairments in other domains could be
affected present
1 Amnestic 1 Amnestic
2 Amnestic + other domain 2 Multidomaina
3 Nonamnestic single domain 3 Nonamnestic single domain,
4 Nonamnestic + other domain
Activities of daily living Normal Normal or they could be minimally affected Normal or they could be minimally affected Normal; complex tasks could be
minimally affected
Clinical impression Not demented Not demented Not demented Not demented
MCI, mild cognitive impairment.
a
With or without memory impairments.
Curr Opin Neurol. Author manuscript; available in PMC 2012 December 1.
Page 20